According to Ian Neeland, MD, there are 2 main reasons for the shortage of injectable semaglutide: the fact that oral semaglutide has not yet been tested for weight loss, and that most practitioners just overlook it as an option.
According to Ian Neeland, MD, the shortage of injectable semaglutide as opposed to the oral version may be attributed to the fact that oral semaglutide has not been tested for weight loss indications, leading to less awareness and utilization. Neeland serves as director of cardiovascular prevention and codirector of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease at the University Hospitals Harrington Heart & Vascular Institute, as well as associate professor of medicine at Case Western Reserve University School of Medicine.
This transcript has been lightly edited for clarity.
Transcript
Why do you think the semaglutide shortage mainly affects the injectable version and not the oral version?
I think 2 reasons. One is that the orals were not tested for the weight loss indication, so there are not weight loss management trials in oral semaglutide as of yet, and so therefore, people just don't have it on their minds—it hasn't been tested, so they don't have it in their minds. But, certainly, there is a weight loss associated with oral semaglutide, although we don't know exactly to what degree compared with injectable semaglutide, that's number 1. Number 2 is that the oral semaglutide—for the same reasons and similar reasons—is just not utilized as much as the injectable type. Although it's certainly been tested for glycemic control and is effective for that, and has been tested for cardiovascular outcomes, and there's actually an ongoing trial looking at oral semaglutide for cardiovascular benefit. It's definitely available, [but] it's kind of been overlooked by most practitioners as an option.
There are a few limitations with oral semaglutide that you don't find with injectable semaglutide. First and foremost, obviously, it's once a day vs once a week. Second of all, you have to take it with a very, very little bit of water and no other medications or food, much like thyroid medication. So the timing of medication can be tricky for people who maybe in the morning aren't as regimented, and they have a difficult time taking different medications at different times, so adherence becomes a problem. And also there are essentially 3 doses at which to treat the patient with, whereas for semaglutide 2.0 there's a little more range of dosing you can do. But it's definitely an appropriate option, a good option, especially for type 2 diabetes management, and potentially off-label for weight loss, although that has not been tested to my knowledge formally in clinical trials.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More